BackgroundThe major adverse consequences of obesity are associated with the development of insulin resistance (IR) and adiposopathy. The Homeostasis Model Assessment-Adiponectin (HOMA-AD) was proposed as a modified version of the HOMA1-IR, which incorporates adiponectin in the denominator of the index.ObjectivesTo evaluate the performance of the HOMA-AD index compared with the HOMA1-IR index as a surrogate marker of IR in women, and to establish the cutoff value of the HOMA-AD.Subjects/MethodsThe Brazilian Metabolic Syndrome Study (BRAMS) is a cross-sectional multicenter survey. The data from 1,061 subjects met the desired criteria: 18–65 years old, BMI: 18.5–49.9 Kg/m² and without diabetes. The IR was assessed by the indexes HOMA1-IR and HOMA-AD (total sample) and by the hyperglycemic clamp (n = 49). Metabolic syndrome was defined using the IDF criteria.ResultsFor the IR assessed by the clamp, the HOMA-AD demonstrated a stronger coefficient of correlation (r = -0.64) compared with the HOMA1-IR (r = -0.56); p < 0.0001. In the ROC analysis, compared with the HOMA1-IR, the HOMA-AD showed higher values of the AUC for the identification of IR based on the clamp test (AUC: 0.844 vs. AUC: 0.804) and on the metabolic syndrome (AUC: 0.703 vs. AUC: 0.689), respectively; p < 0.001 for all. However, the pairwise comparison did not show evidence of superiority for the HOMA-AD in comparison with the HOMA1-IR in the diagnosis of IR and metabolic syndrome (p > 0.05). The optimal cutoff identified for the HOMA-AD for the diagnosis of IR was 0.95.ConclusionsThe HOMA-AD index was demonstrated to be a useful surrogate marker for detecting IR among adult women and presented a similar performance compared with the HOMA1-IR index. These results may assist physicians and researchers in determining which method to use to evaluate IR in light of the available facilities.

Prevalence of GDM is minimally altered by the new WHO definition. Although GDM is a common condition, the vast majority of the cases have hyperglycaemia in the range considered impaired glucose tolerance outside pregnancy.

These findings show a high incidence of LEAs in Brazil, when compared to countries such as Spain, that is attributable mainly to peripheral vascular disease and diabetes mellitus.

RESUMODiabetes mellitus (DM) é uma doença progressiva que apresenta complicações freqüentes, em especial a infecção nos pés. Realizamos um estudo prospectivo com 141 pacientes com DM e úlceras infectadas nos pés, conduzido no Centro Integrado de Diabetes e Hipertensão da UFC no período de março/2000 a novembro/2001. A maioria apresentava infecção avaliada como graus I e II da classificação de Wagner. As amostras foram cultivadas utilizando-se meios seletivos, e a identificação bacteriana e os antibiogramas foram realizados através de metodologia convencional e automatizados. Os patógenos mais freqüentemente isolados foram as enterobactérias (83,7%), Staphylococcus aureus (43,3%) e bactérias anaeróbias (17%). Cepas de Streptococcus pyogenes foram isoladas de 7,8% dos pacientes. Cepas produtoras de beta-lactamase de espectro ampliado e cepas de Staphylococcus aureus resistentes à oxacilina foram isoladas de 6% e 11,6% dos pacientes, respectivamente. A resistência aos antimicrobianos vem se tornando cada vez mais comum, mesmo em pacientes com infecção adquirida na comunidade. Investimentos em diagnóstico etiológico das infecções e estratégias racionais no uso de antimicrobianos fazem-se necessários na tentativa de evitar tratamentos inadequados e suas já conhecidas conseqüências. In a prospective study, we analyzed 298 species of bacteria isolated from 141 patients with community-acquired diabetic foot ulcers. The study was undertaken at a diabetic center and at the Federal University of Ceará, Brazil, from March/2000 to November/2001. The majority of patients had mild to moderate infections and was classified as Wagner's grades I and II. The samples were cultured using selective media. The identification and the susceptibility tests were done by conventional and automated methods. The most frequently occurring pathogens were Enterobacteriaceae (83.7%), Staphylococcus aureus (43.3%) and anaerobic bacteria (17%). Streptococcus pyogenes was recovered from 7.8% of the patients. ESBL producing strains were detected in 6% and methicillin resistant Staphylococcus aureus strains were recovered from 11.6% of the patients. Resistance among bacteria has increased largely, and became common even in community-acquired infections. Improvements in the routine etiologic diagnostics and antibiotic use strategies are required to avoid inadequate treatment and its well known dramatic consequences.

Background: In current management of type 2 diabetes (T2DM), cardiovascular and renal prevention have become important targets to be achieved. In this context, a joint panel of four endocrinology societies from Brazil and Portugal was established to develop an evidence-based guideline for treatment of hyperglycemia in T2DM. Methods: MEDLINE (via PubMed) was searched for randomized clinical trials, meta-analyses, and observational studies related to diabetes treatment. When there was insufficient high-quality evidence, expert opinion was sought. Updated positions on treatment of T2DM patients with heart failure (HF), atherosclerotic CV disease (ASCVD), chronic kidney disease (CKD), and patients with no vascular complications were developed. The degree of recommendation and the level of evidence were determined using predefined criteria. Results and conclusions: In non-pregnant adults, the recommended HbA 1c target is below 7%. Higher levels are recommended in frail older adults and patients at higher risk of hypoglycemia. Lifestyle modification is recommended at all phases of treatment. Metformin is the first choice when HbA 1c is 6.5-7.5%. When HbA 1c is 7.5-9.0%, dual therapy with metformin plus an SGLT2i and/or GLP-1 RA (first-line antidiabetic agents, AD1) is recommended due to cardiovascular and renal benefits. If an AD1 is unaffordable, other antidiabetic drugs (AD) may be used. Triple or quadruple therapy should be considered when HbA 1c remains above target. In patients with clinical or subclinical atherosclerosis, the combination of one AD1 plus metformin is the recommended first-line therapy to reduce cardiovascular events and improve blood glucose control. In stable heart failure with low ejection fraction (< 40%) and glomerular filtration